Response Genetics starts researching pancreatic cancer test:
This article was originally published in Clinica
Executive Summary
Response Genetics has initiated a two-year research study geared towards the development of a diagnostic test kit for pancreatic cancer. Los Angeles, California-based Response Genetics' technologies enable the extraction and analysis of genetic information from genes derived from formalin-fixed and paraffin embedded tumour samples. This information can be combined with patient outcomes data to aid in the development of assays and diagnostic tests for pancreatic cancer. The study will be conducted in collaboration with the University of California at San Francisco (UCSF), which will provide the tissue samples. According to the American Cancer Society, 33,370 US citizens will die from pancreatic cancer this year, with around 37,170 new cases being diagnosed in the US.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.